Topic summary

Enforcement priorities versus written rules — does this still hold?

Sourcing › Regulatory EMA MHRA compounding FDA Solved Under review

This is a generated summary. It shows the 6 most-liked posts from a topic of 41, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

r.oyelaranTL2 Moderator5 Aug 2025#1

Enforcement priorities versus written rules — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked.

Structured report rather than an opinion, following the format the maintainers asked for.

Compound: semaglutide
Independent testing: Medutest
Method as reported: reversed-phase HPLC, 280 nm
Result: 97.3% area
Certificate figure for the same lot: 98.3%

I am not drawing a conclusion about the supplier from one lot and I would ask that nobody else does either. I am adding a data point to a record.

27 likes 12mo

OTeixeiraTL3Regular7 Aug 2025#2

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

29 likes 12mo

s.vogelTL2 Moderator Solution10 Aug 2025 · edited#5

Approval versus licensing: a compound can be approved for a specific indication in one country and not approved at all in another. Tracking jurisdictional approval is tedious but necessary.

21 likes 12mo

erratum_fileTL3Regular18 Aug 2025#17

On post #13 — agreed on the reasoning, with one qualification.

Preclinical versus clinical: compounds with strong preclinical data can fail in clinical trials. Compounds with no human data are being used on theoretical grounds. The regulatory position reflects this asymmetry.

25 likes 11mo

y.mensahTL3Wiki editor27 Aug 2025#32

Ridgeway, post #15: Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption. The label does not establish whether the molecule is safe, efficacious, or toxic. Go to post

post #31 is right about the mechanism and I think understates the practical bit.

Labelling and intended use: a compound sold as "research-use-only" does not change its pharmacology if ingested. It changes the legal status of the sale. The labelling tells you the intended use, not the actual use people make of it.

29 likes in reply to #15 11mo

ar.kravchenkoTL2 Moderator31 Aug 2025#39

s.vukovic, post #35: Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal use depends on your country's rules, not on where it is sold. Go to post

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

30 likes in reply to #35 11mo

Read the full topic (41 posts)

This topic was referenced in

Coming back to: Research-use-only labelling: what it means and what it does notSourcing › Regulatory · 50 replies
Revisiting: Why a compound being unapproved is not the same as being illegal to possessSourcing › Regulatory · 82 replies
Reading a regulatory notice rather than an article about it — what changed sinceSourcing › Regulatory · 32 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Research-use-only labelling: what it means and what it does not — the long version Sourcing › Regulatory EMA research use only compounding Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not — the long version Everything below is what sits behind that. I would like to talk about…	+150	158	55k	14mo
Reading a regulatory notice rather than an article about it Sourcing › Regulatory compounding personal import EMA Posting this under the heading it deserves: Reading a regulatory notice rather than an article about it Everything below is what sits behind that. Structured report rather than an opinion, following the…		2	2.9k	5mo
Reading a regulatory notice rather than an article about it — what changed since Sourcing › Regulatory research use only MHRA FDA personal import Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable. A logistics question, since the answers here are usually…	+28	32	640	13mo
What a regulator's shortage notice actually authorises — what changed since Sourcing › Regulatory research use only EMA FDA compounding Solved The question in the title: What a regulator's shortage notice actually authorises — what changed since I will give what I have already checked below so nobody repeats it. A logistics question, since the…	+22	26	53k	7mo
Second pass at: Import rules for personal quantities, by jurisdiction, dated Sourcing › Regulatory research use only personal import FDA MHRA Second pass at: Import rules for personal quantities, by jurisdiction, dated Writing it up because I had to work it out twice and would rather nobody else did. A logistics question, since the answers here are…		2	5k	11mo

Related topics — sharing the tags EMA, MHRA, compounding

Topic	Participants	Replies	Views	Activity
Cross-border purchase rules within the EU Regional › European Union personal import formulary cost per milligram EMA On the subject in the title: Cross-border purchase rules within the EU Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what determines the answer.…	+45	49	15k	8mo
Why the cheapest option is often not the cheapest Access › Pricing compounding formulary cost per milligram data table Solved Wiki Why the cheapest option is often not the cheapest I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated, because everything in this…	+19	23	1.2k	12h
Price changes over 2025 and 2026, tabulated and dated Access › Pricing formulary cost per milligram data table compounding Posting this under the heading it deserves: Price changes over 2025 and 2026, tabulated and dated Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this…	+4	8	658	14mo
Cost per delivered dose, which is the number that matters Access › Pricing cost per milligram data table compounding formulary Solved Cost per delivered dose, which is the number that matters — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what…	+54	59	30k	4mo
Prescription portability between countries — the long version Access › International EMA NHS telehealth On the subject in the title: Prescription portability between countries — the long version Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category…		2	182	21h